TTrialPathMatch Me to Trials
← Back to trials
RecruitingKnee Cartilage Defects

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

Eligible age

18–75 yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will test whether CARTISTEM is safe and works better than debridement (a surgery that cleans out damaged tissue) for people with knee cartilage damage and osteoarthritis. CARTISTEM is a new treatment made of stem cells from donated umbilical cord blood mixed with a gel (hyaluronic acid) that is placed in the damaged area of the knee The main goal is to find out if CARTISTEM® reduces knee pain and improves knee function more than debridement two years after treatment. The study will also use MRI scans to explore whether CARTISTEM® may slow the worsening of osteoarthritis over time.

Sponsor: Medipost, Inc.

You may qualify if…

  • ✓ 1. Age ≥ 18 and ≤ 75 years old.
  • ✓ 2. Knee Osteoarthritis diagnosed in the index knee according to the clinical definition of American College of Rheumatology (ACR) guidelines at screening.
  • ✓ 3. Failed conservative knee osteoarthritis treatment for at least 3 months prior to consent (weight reduction, physical therapy, injections, pain medications, etc.).
  • ✓ 4. Kellgren-Lawrence (KL) in the index knee of grade 2 to 3 as determined by independent radiologist review of study X-Ray.
  • ✓ 5. Clinically relevant femoral cartilage defects classified using modified Outerbridge Grade 3 or 4 in index knee with combined lesion area ≥ 2 cm2 and ≤ 9 cm2 and at least a single femoral lesion ≥ 2 cm2 as determined by independent radiologist review of study MRI.
  • ✓ 6. Body Mass Index (BMI) ≤ 35 kg / m2 .
  • ✓ 7. VAS PAIN index knee score ≥ 40 to ≤ 90 based on 100-point scale at screening.
  • ✓ 8. VAS PAIN contralateral knee score ≤ 30 based on 100-point scale at screening.

You may not qualify if…

  • ✕ 1. Subject received an IA injection of Hyaluronic Acid (HA), Platelet Rich Plasma (PRP), Bone Marrow Aspirate / Concentrate (BMA / BMAC), long-acting / conventional steroid, or investigational drug in either knee within 3 months of signing informed consent. Note: injections of the contralateral knee are allowed during the trial.
  • ✕ 2. Bone marrow lesion (BML) grade 3 on femur, tibia, or patella except at femoral lesion area (BML grade 3 allowed) in index knee as determined by independent radiologist review of study MRI.
  • ✕ 3. KL index knee grade 0, 1 or 4 as determined by independent radiologist review of study X-Ray.
  • ✕ 4. KL Contralateral knee severity grade 4 as determined by independent radiologist review of study X-Ray.
  • ✕ 5. Anatomical axis varus or valgus malalignment ≥ 6° in either knee as determined by independent radiologist.
  • ✕ 6. Joint ligament instability in index knee ≥ Grade 3 or ligament instability that would require surgical intervention as determined by investigator or designee.
  • ✕ 7. Complete meniscal deficiency, meniscal root tears and / or severe meniscal extrusion as determined by independent radiologist.
  • ✕ 8. Kissing bipolar lesions (tibial or patellar) Outerbridge 4 exceeding 25% of the femoral lesion area in size and/or penetrating through the subchondral bone as determined by independent radiologist.

Where it's recruiting

Alabama

Birmingham

Arizona

Scottsdale · Tempe

California

El Cajon · Encinitas · Irvine · La Jolla …

Colorado

Parker · Steamboat Springs

Florida

Deerfield Beach · Miami

Illinois

Chicago

Kentucky

Lexington

Louisiana

Kenner

Michigan

Ann Arbor · Rochester Hills

Minnesota

Rochester

New Jersey

Westwood

Source: ClinicalTrials.gov · NCT07339111 · last updated 2026-11-18

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for · TrialPath